These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18057188)

  • 61. How to identify and treat data inconsistencies when eliciting health-state utility values for patient-centered decision making.
    Triantaphyllou E; Yanase J
    Artif Intell Med; 2020 Jun; 106():101882. PubMed ID: 32593392
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Individual utilities are inconsistent with rationing choices: A partial explanation of why Oregon's cost-effectiveness list failed.
    Ubel PA; Loewenstein G; Scanlon D; Kamlet M
    Med Decis Making; 1996; 16(2):108-16. PubMed ID: 8778528
    [TBL] [Abstract][Full Text] [Related]  

  • 63. What is the best model for estimating joint health states utilities? Comparing the linear index model to the proportional decrement model.
    Dale W
    Med Decis Making; 2010; 30(5):531-3. PubMed ID: 20959507
    [No Abstract]   [Full Text] [Related]  

  • 64. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer.
    Saigal CS; Gornbein J; Reid K; Litwin MS
    Qual Life Res; 2002 Aug; 11(5):405-14. PubMed ID: 12113388
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble.
    Cook KF; Ashton CM; Byrne MM; Brody B; Geraci J; Giesler RB; Hanita M; Souchek J; Wray NP
    Soc Sci Med; 2001 Nov; 53(10):1275-85. PubMed ID: 11676400
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Deriving welfare measures in discrete choice experiments: a comment to Lancsar and Savage (1).
    Ryan M
    Health Econ; 2004 Sep; 13(9):909-12; discussion 919-24. PubMed ID: 15362182
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A review and meta-analysis of prostate cancer utilities.
    Bremner KE; Chong CA; Tomlinson G; Alibhai SM; Krahn MD
    Med Decis Making; 2007; 27(3):288-98. PubMed ID: 17502448
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patient perceptions of quality of life with diabetes-related complications and treatments.
    Huang ES; Brown SE; Ewigman BG; Foley EC; Meltzer DO
    Diabetes Care; 2007 Oct; 30(10):2478-83. PubMed ID: 17623824
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The utility of health states after stroke: a systematic review of the literature.
    Post PN; Stiggelbout AM; Wakker PP
    Stroke; 2001 Jun; 32(6):1425-9. PubMed ID: 11387509
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance.
    Elstein AS; Chapman GB; Chmiel JS; Knight SJ; Chan C; Nadler RB; Kuzel TM; Siston AK; Bennett CL
    Health Expect; 2004 Jun; 7(2):115-25. PubMed ID: 15117386
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Utility Estimates of Disease-Specific Health States in Prostate Cancer from Three Different Perspectives.
    Gries KS; Regier DA; Ramsey SD; Patrick DL
    Appl Health Econ Health Policy; 2017 Jun; 15(3):375-384. PubMed ID: 27704390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited?
    Essink-Bot ML; Korfage IJ; De Koning HJ
    BJU Int; 2003 Dec; 92 Suppl 2():101-5. PubMed ID: 14983965
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient utilities for advanced cancer: effect of current health on values.
    Wittenberg E; Winer EP; Weeks JC
    Med Care; 2005 Feb; 43(2):173-81. PubMed ID: 15655431
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Acute and chronic impact of cardiovascular events on health state utilities.
    Matza LS; Stewart KD; Gandra SR; Delio PR; Fenster BE; Davies EW; Jordan JB; Lothgren M; Feeny DH
    BMC Health Serv Res; 2015 Apr; 15():173. PubMed ID: 25896804
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Biases from omitted risk effects in standard gamble utilities.
    Pope R
    J Health Econ; 2004 Jul; 23(4):695-735. PubMed ID: 15587695
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Measurement of health state utilities for economic appraisal.
    Torrance GW
    J Health Econ; 1986 Mar; 5(1):1-30. PubMed ID: 10311607
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multi-method approach to valuing health states: problems with meaning.
    Nord E; Menzel P; Richardson J
    Health Econ; 2006 Feb; 15(2):215-8. PubMed ID: 16389641
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.
    Meghani SH; Lee CS; Hanlon AL; Bruner DW
    BMC Med Inform Decis Mak; 2009 Nov; 9():47. PubMed ID: 19941668
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A theoretical framework for TTO valuations of health.
    Buckingham K; Devlin N
    Health Econ; 2006 Oct; 15(10):1149-54. PubMed ID: 16786547
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship.
    O'Leary JF; Fairclough DL; Jankowski MK; Weeks JC
    Med Decis Making; 1995; 15(2):132-7. PubMed ID: 7783573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.